TTUHSC researchers testing drug compounds for alcohol use disorder treatments
A pharmaceutical product used to treat bacterial infections could be a key player in helping treat alcohol use disorder.
Susan E. Bergeson, Ph.D., associate professor in the department of pharmacology and neuroscience at the Texas Tech University Health Sciences Center, said she and her team have been studying the effects of a drug classified as tetracycline in mice with AUD.
Read the full story here.
Related Stories
TTUHSC School of Nursing to Celebrate New YWCA Location
Community members in central Lubbock now have access to health care services and prenatal programs at one location inside the YWCA.
A Rite of Passage for Next Generation of Physicians
Students in TTUHSC's School of Medicine Class of 2028 received their first white coat and pledged their commitment to the medical profession at the White Coat Ceremony Friday (July 26) at the Buddy Holly Hall of Performing Arts and Sciences.
How Does Your Garden Grow?
As spring approaches, some people’s thoughts turn to gardening. Whether it’s a flower garden they desire or a vegetable garden want to have, they begin planning what they’ll plant and what they need to do to ensure a successful garden.
Recent Stories
Alumni Spotlight: Sister Duo Offers Local, Personalized Allied Health Services
Abagale (Abby) Chapman, OT (2014), and Hannah Cowden, SLP (2017), are sisters working together to help children in Lubbock and the surrounding areas become the greatest version of themselves.
TTUHSC Faculty Receive Chancellor’s Council Distinguished Teaching and Research Awards
Recognizing academic excellence, the honors are the most prestigious awards granted to faculty throughout the TTU System.
TTUHSC Researchers Developing Lupus Treatment
Jon McCord, Ph.D., a recent postdoc at the TTUHSC School of Medicine, and Bryan Sutton, Ph.D., from TTUHSC’s Department of Cell Physiology and Molecular Biophysics, study a mutation in a specific protein found in lupus patients. Together, they aim to become the force behind this new, patent pending therapy.